483 related articles for article (PubMed ID: 19293196)
1. Impact of intravenous {beta}-lactam/macrolide versus {beta}-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia.
Tessmer A; Welte T; Martus P; Schnoor M; Marre R; Suttorp N
J Antimicrob Chemother; 2009 May; 63(5):1025-33. PubMed ID: 19293196
[TBL] [Abstract][Full Text] [Related]
2. Empiric treatment in hospitalized community-acquired pneumonia. Impact on mortality, length of stay and re-admission.
Reyes Calzada S; Martínez Tomas R; Cremades Romero MJ; Martínez Moragón E; Soler Cataluña JJ; Menéndez Villanueva R
Respir Med; 2007 Sep; 101(9):1909-15. PubMed ID: 17628462
[TBL] [Abstract][Full Text] [Related]
3. Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project.
Bratzler DW; Ma A; Nsa W
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S193-201. PubMed ID: 18986289
[TBL] [Abstract][Full Text] [Related]
4. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
Lodise TP; Kwa A; Cosler L; Gupta R; Smith RP
Antimicrob Agents Chemother; 2007 Nov; 51(11):3977-82. PubMed ID: 17709460
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of empiric β-lactam monotherapy and β-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia.
Ambroggio L; Taylor JA; Tabb LP; Newschaffer CJ; Evans AA; Shah SS
J Pediatr; 2012 Dec; 161(6):1097-103. PubMed ID: 22901738
[TBL] [Abstract][Full Text] [Related]
6. Mortality in patients with community-onset pneumonia at low risk of drug-resistant pathogens: Impact of β-lactam plus macrolide combination therapy.
Okumura J; Shindo Y; Takahashi K; Sano M; Sugino Y; Yagi T; Taniguchi H; Saka H; Matsui S; Hasegawa Y;
Respirology; 2018 May; 23(5):526-534. PubMed ID: 29239493
[TBL] [Abstract][Full Text] [Related]
7. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
Garin N; Genné D; Carballo S; Chuard C; Eich G; Hugli O; Lamy O; Nendaz M; Petignat PA; Perneger T; Rutschmann O; Seravalli L; Harbarth S; Perrier A
JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173
[TBL] [Abstract][Full Text] [Related]
8. Moxifloxacin monotherapy versus ß-lactam mono- or combination therapy in hospitalized patients with community-acquired pneumonia.
Ewig S; Hecker H; Suttorp N; Marre R; Welte T;
J Infect; 2011 Mar; 62(3):218-25. PubMed ID: 21276814
[TBL] [Abstract][Full Text] [Related]
9. The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis.
Paul M; Nielsen AD; Gafter-Gvili A; Tacconelli E; Andreassen S; Almanasreh N; Goldberg E; Cauda R; Frank U; Leibovici L
Eur Respir J; 2007 Sep; 30(3):525-31. PubMed ID: 17537772
[TBL] [Abstract][Full Text] [Related]
10. Impact of guideline-concordant antibiotics and macrolide/β-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study.
Asadi L; Eurich DT; Gamble JM; Minhas-Sandhu JK; Marrie TJ; Majumdar SR
Clin Microbiol Infect; 2013 Mar; 19(3):257-64. PubMed ID: 22404691
[TBL] [Abstract][Full Text] [Related]
11. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
12. Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials.
An MM; Zou Z; Shen H; Gao PH; Cao YB; Jiang YY
Int J Antimicrob Agents; 2010 Jul; 36(1):58-65. PubMed ID: 20400271
[TBL] [Abstract][Full Text] [Related]
13. β-Lactam/macrolide dual therapy versus β-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis.
Nie W; Li B; Xiu Q
J Antimicrob Chemother; 2014 Jun; 69(6):1441-6. PubMed ID: 24535276
[TBL] [Abstract][Full Text] [Related]
14. Antibiotic treatment strategies for community-acquired pneumonia in adults.
Postma DF; van Werkhoven CH; van Elden LJ; Thijsen SF; Hoepelman AI; Kluytmans JA; Boersma WG; Compaijen CJ; van der Wall E; Prins JM; Oosterheert JJ; Bonten MJ;
N Engl J Med; 2015 Apr; 372(14):1312-23. PubMed ID: 25830421
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis and management of community-acquired pneumonia in adults.
Watkins RR; Lemonovich TL
Am Fam Physician; 2011 Jun; 83(11):1299-306. PubMed ID: 21661712
[TBL] [Abstract][Full Text] [Related]
16. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
17. [What is new in the treatment of community-acquired pneumonia?].
Welte T; Marre R; Suttorp N;
Med Klin (Munich); 2006 Apr; 101(4):313-20. PubMed ID: 16607488
[TBL] [Abstract][Full Text] [Related]
18. Moxifloxacin versus standard therapy in patients with pneumonia hospitalized after failure of preclinical anti-infective treatment.
Wenisch C; Krause R; Széll M; Laferl H
Infection; 2006 Aug; 34(4):190-5. PubMed ID: 16896576
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic treatment of community acquired pneumonia varies widely across Germany.
Kohlhammer Y; Raspe H; Marre R; Suttorp N; Welte T; Schäfer T;
J Infect; 2007 May; 54(5):446-53. PubMed ID: 17007933
[TBL] [Abstract][Full Text] [Related]
20. The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization.
Peyrani P; Wiemken TL; Metersky ML; Arnold FW; Mattingly WA; Feldman C; Cavallazzi R; Fernandez-Botran R; Bordon J; Ramirez JA
Infect Dis (Lond); 2018 Jan; 50(1):13-20. PubMed ID: 28699429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
